Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Hepatitis Delta a Major Global Problem: Screening, Diagnosis, and Treatment in 2022 – Physician Discussion #1

In this podcast, CCO’s expert faculty discusses HDV epidemiology beyond the United States, the features of HDV/HBV pathology, insights into screening and diagnostic approaches, key aspects of disease staging, new treatment options, and important remaining clinical questions regarding optimal management of HDV.
Heiner Wedemeyer, MD
Released: March 30, 2022

In this episode, Heiner Wedemeyer, MD, discusses HDV epidemiology beyond the United States, the features of HDV/HBV pathology, insights into screening and diagnostic approaches, key aspects of disease staging, new treatment options, and important remaining clinical questions regarding optimal management of HDV.

Information on this Educational Activity

Faculty

Heiner Wedemeyer, MD

Professor and Chairman
Department of Gastroenterology, Hepatology and Endocrinology
Hannover Medical School
Hannover, Germany

Heiner Wedemeyer, MD, has disclosed that he has received consulting fees from AbbVie, Aligos, Altimmune, Biotest, Bristol-Myers Squibb, BTG, Dicerna, Enanta, Gilead, Janssen, Merck/MSD, MYR, Roche, and Vir; has received funds for research support from AbbVie, Biotest, Gilead, Merck/MSD, and Roche; and has served as a clinical trials investigator for AbbVie, Altimmune, Bristol-Myers Squibb, Gilead, Janssen, Merck/MSD, MYR, Novartis, and Vir.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
AbbVie
Gilead Sciences, Inc.

Related Content

Prof George Lau: proactive monitoring and treatment are necessary for all patients with CHB, regardless of age, from Clinical Care Options (CCO)

George Lau, MBBS (HKU), MD (HKU), FRCP (Edin, Lond), FAASLD (USA) Released: December 1, 2022

Expert summaries of AASLD, EASL, APASL guidance on monitoring and treating chronic hepatitis B and delta infections, with Maria Buti, Paul Kwo, Grace Wong

Maria Buti, MD Paul Y. Kwo, MD Grace LH Wong, MD Released: December 1, 2022

Expert summaries of AASLD, EASL, and APASL guidance on monitoring and treating chronic hepatitis B and delta viral infections, from Clinical Care Options (CCO)

Maria Buti, MD Paul Y. Kwo, MD Grace LH Wong, MD Released: December 1, 2022

Expert summaries of key data in older patients with HBV, from Clinical Care Options (CCO)

Graham R. Foster, FRCP, PhD Nancy Reau, MD Released: November 16, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings